Advertisement
"This Series B round represents not only an infusion of capital but theaddition of two world class investor groups, Alta Partners and ClarusVentures, represented on our Board respectively by Edward Hurwitz and NicholasGalakatos, PhD," said Timothy Mills, PhD, Chairman of the Board of Taligen."The progress made since our original investment in 2005 now allows us todevelop multiple products to control the alternative pathway of complementactivation. With this additional funding, we expect to move into clinicaldevelopment with all of our lead candidates."
Advertisement
About Taligen: Founded in 2004, Taligen Therapeutics, Inc. is adevelopment-stage biotechnology company with novel technology and expertisefocused on modulation and control of the complement system. The complementsystem is believed to be a critical component in the initiation ofinflammation. Complement system activation is characteristic of many humandiseases, including asthma, macular degeneration, rheumatoid arthritis andimmune renal disease.
Taligen's lead products are monoclonal antibodies and recombinant fusionproteins which target key factors in the alternative complement pathway. Theseproducts are in preclinical stages of development to treat systemic as well aslocal inflammatory conditions.
The Company was founded by Drs. Woodruff Emlen and V. Michael Holers basedon technology and intellectual property predominantly from the University ofColorado at Denver and Health Sciences Center (UCDHSC) and partneringinstitutions. Dr. Holers is currently Professor of Medicine at UCDHSC and Dr.Emlen is a former Professor of Medicine and Immunology at UCDHSC.
This release is for informational purposes only and it does not constitutean offer to sell or the solicitation of an offer to buy any of the securitiesnor shall there be any sale of these securities in any state in which suchoffer, solicitation or sale would be unlawful prior to registration orqualification of the securities under the securities laws of any such state.Contact: Tony Russo, Ph.D. Russo Partners, LLC [email protected] 1 212 845 4251
SOURCE Taligen Therapeutics, Inc.
